AMG National Trust Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

AMG National Trust Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-23,891	Closed	-$1.29M	–	458
2025 Q3	$1.29M	Sell	23,891 -422	-2%	-$24.1K	0.03%	263
2025 Q2	$1.34M	Buy	24,313 +22	+0.1%	+$1.3K	0.04%	260
2025 Q1	$1.72M	Buy	+24,291	New	+$1.63M	0.05%	215

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AMG National Trust Bank's BMRN Position: Q4 2025 in Review

AMG National Trust Bank sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 23,891 shares — an estimated $1.29M sold.

AMG National Trust Bank first reported a position in BMRN in Q1 2025 and held it in 3 quarters. The position peaked at $1.72M in Q1 2025. 541 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

AMG National Trust Bank reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
AMG National Trust Bank sold 23,891 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.29M.
AMG National Trust Bank first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 3 quarters.
AMG National Trust Bank's BioMarin Pharmaceuticals position peaked at $1.72M in Q1 2025.
541 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on AMG National Trust Bank's 13F filing for Q4 2025, filed 30 Jan 2026.